Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Prevnar 13 (PCV13), a 13-valent pneumococcal conjugate vaccine, which had been available for pediatric use since 2010, was approved at the end of 2011 by the FDA for the prevention of pneumonia and invasive disease caused by included serotypes in adults 50 years of age and older.

Conjugate Pneumococcal Vaccine and Adults